Reference for Chapter 92: Hidradenitis Suppurativa

1 Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619. Cross Ref link Pubmed link
2 Velpeau AA. In: Bechet JZ, ed. Dictionnaire de Médecine, un Repertoire Générale des Sciences Medicals sous le Rapport Theorique et Pratique, Vol. 2. Paris, 1839:1839–91.
3 Verneuil A. De L'hidrosadenite phlegmoneuse et des abces sudoripares. Arch Gen Med 1864;2:537–57.
4 Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigh R, Roenigh H, eds. Dermatologic Surgery. New York: Marcel Dekker, 1989:729–39.
5 Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011;91:328–32. Cross Ref link Pubmed link
6 Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010;90:264–8. Cross Ref link Pubmed link
7 Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population‐based study of Olmsted County, Minnesota. J Invest Dermatol 2013;133:97–103. Cross Ref link Pubmed link
8 Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population‐based study of possible hidradenitis suppurativa. Br J Dermatol 2014;170:884–9. Cross Ref link Pubmed link
9 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–4. Cross Ref link Pubmed link
10 Revuz JE, Canoui‐Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case‐control studies. J Am Acad Dermatol 2008;59:596–601. Cross Ref link Pubmed link
11 Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013;68:412–19. Cross Ref link Pubmed link
12 Schrader AM, Deckers IE, van der Zee HH, et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014;71:460–7. Cross Ref link Pubmed link
13 Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988;119:345–50. Cross Ref link Pubmed link
14 Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology 2010;2:9–16. Cross Ref link
15 Van der Zee HH, van der Woude CJ, Florencia EF, et al. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010;162:195–7. Cross Ref link Pubmed link
16 Meskin SW, Carlson EM. Mooren's‐type ulceration associated with severe hidradenitis suppurativa: a case report and literature review. Ocul Immunol Inflamm 2011;19:340–2. Cross Ref link Pubmed link
17 Van der Zee HH, Laman JD, Boer J, et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012;21:735–9. Pubmed link
18 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539–61. Cross Ref link Pubmed link
19 Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009;161:831–9. Cross Ref link Pubmed link
20 Kromann CB, Ibler KS, Kristiansen VB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 2014;94:553–7. Cross Ref link Pubmed link
21 Konig A, Lehmann C, Rompel R, et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999;198:261–4. Cross Ref link Pubmed link
22 Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre‐ and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996;134:1057–9. Cross Ref link Pubmed link
23 Dvorak VC, Root RK, MacGregor RR. Host‐defense mechanisms in hidradenitis suppurativa. Arch Dermatol 1977;113:450–3. Cross Ref link Pubmed link
24 Giamarellos‐Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007;156:51–6. Cross Ref link Pubmed link
25 Van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)‐alpha, interleukin (IL)‐1beta and IL‐10 in hidradenitis suppurativa skin: a rationale for targeting TNF‐alpha and IL‐1beta. Br J Dermatol 2011;164:1292–8. Cross Ref link Pubmed link
26 Van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor‐alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2012;166:298–305. Cross Ref link Pubmed link
27 Schlapbach C, Hanni T, Yawalkar N, et al. Expression of the IL‐23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011;65:790–8. Cross Ref link Pubmed link
28 Dreno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012;148:182–6. Cross Ref link Pubmed link
29 Hunger RE, Surovy AM, Hassan AS, et al. Toll‐like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C‐type lectin receptor. Br J Dermatol 2008;158:691–7. Cross Ref link Pubmed link
30 Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL‐22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011;186:1228–39. Cross Ref link Pubmed link
31 Schlapbach C, Yawalkar N, Hunger RE. Human beta‐defensin‐2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol 2009;61:58–65. Cross Ref link Pubmed link
32 Bechara FG, Sand M, Skrygan M, et al. Acne inversa: evaluating antimicrobial peptides and proteins. Ann Dermatol 2012;24:393–7. Cross Ref link Pubmed link
33 Hofmann SC, Saborowski V, Lange S, et al. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol 2012;66:966–74. Cross Ref link Pubmed link
34 Marinella MA. Lithium therapy associated with hidradenitis suppurativa. Acta Derm Venereol 1997;77:483. Pubmed link
35 Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J 2013;19:18558. Pubmed link
36 Van der Zee HH, de Ruiter L, Boer J, et al. Alterations in leucocyte subsets and histomorphology in normal‐appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012;166:98–106. Cross Ref link Pubmed link
37 Kamp S, Fiehn AM, Stenderup K, et al. Sebaceous gland number and volume is significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011;164:1017–22. Cross Ref link Pubmed link
38 Jemec GB, Faber M, Gutschik E, et al. The bacteriology of hidradenitis suppurativa. Dermatology 1996;193:203–6. Cross Ref link Pubmed link
39 Lapins J, Jarstrand C, Emtestam L. Coagulase‐negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999;140:90–5. Cross Ref link Pubmed link
40 Sartorius K, Killasli H, Oprica C, et al. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol 2012;166:879–83. Cross Ref link Pubmed link
41 Lapins J, Olerup O, Emtestam L. No human leukocyte antigen‐A, ‐B or ‐DR association in Swedish patients with hidradenitis suppurativa. Acta Derm Venereol 2001;81:28–30. Cross Ref link Pubmed link
42 Wang B, Yang W, Wen W, et al. Gamma‐secretase gene mutations in familial acne inversa. Science 2010;330:1065. Cross Ref link Pubmed link
43 Pink AE, Simpson MA, Desai N, et al. Gamma‐secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 2013;133:601–7. Cross Ref link Pubmed link
44 Melnik BC, Plewig G. Impaired Notch‐MKP‐1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol 2013;22:172–7. Cross Ref link Pubmed link
45 Canoui‐Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross‐sectional study. J Invest Dermatol 2013;133:1506–11. Cross Ref link Pubmed link
46 Sartorius K, Killasli H, Heilborn J, et al. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol 2010;162:1261–8. Cross Ref link Pubmed link
47 Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014;171:1434–42. Cross Ref link Pubmed link
48 Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473–8. Cross Ref link Pubmed link
49 Von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000;14:389–92. Cross Ref link Pubmed link
50 Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long‐term prognosis in hidradenitis suppurativa: a cross‐sectional study. Br J Dermatol 2014;171:819–24. Cross Ref link Pubmed link
51 Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983;22:325–8. Cross Ref link Pubmed link
52 Boer J, Jemec GB. Resorcinol peels as a possible self‐treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010;35:36–40. Cross Ref link Pubmed link
53 Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998;39:971–4. Cross Ref link Pubmed link
54 Van der Zee HH, Boer J, Prens EP, et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143–7. Cross Ref link Pubmed link
55 Gener G, Canoui‐Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009;219:148–54. Cross Ref link Pubmed link
56 Join‐Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin‐moxifloxacin‐metronidazole combination therapy in hidradenitis suppurativa. Dermatology 2011;222:49–58. Cross Ref link Pubmed link
57 Blok JL, van Hattem S, Jonkman MF, et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 2013;168:243–52. Cross Ref link Pubmed link
58 Jemec GB, Sundaram M, Pinsky B, Gu Y, Williams D, Bao Y. Adalimumab improves treatment satisfaction with medication (TS‐M) in patients with moderate to severe hidradenitis suppurativa (HS) in a 12‐week randomised controlled trial (PIONEER I). J Invest Dermatol 2014;134:S30–8. Cross Ref link
59 Jemec G, Gottlieb A, Forman S, et al. Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a Phase 3 randomized placebo‐controlled trial [Abstract FC08.2]. In: 23rd EADV Congress: Building Bridges. Amsterdam: European Academy of Dermatology and Venereology, 2014. http://eadvamsterdam2014‐m.poken.com/event/92466382/product/100251716/description (last accessed June 2015).
60 Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double‐blind, placebo‐controlled crossover trial. J Am Acad Dermatol 2010;62:205–17. Cross Ref link Pubmed link
61 Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open‐label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009;60:565–73. Cross Ref link Pubmed link
62 Brocard A, Knol AC, Khammari A, et al. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007;214:325–7. Cross Ref link Pubmed link
63 Goo B, Chung HJ, Chung WG, et al. Intramuscular immunoglobulin for recalcitrant suppurative diseases of the skin: a retrospective review of 63 cases. Br J Dermatol 2007;157:563–8. Cross Ref link Pubmed link
64 Verdolini R, Clayton N, Smith A, et al. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 2013;27:1101–8. Cross Ref link Pubmed link
65 O'Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg 2005;116:1575–6. Cross Ref link Pubmed link
66 Ritz JP, Runkel N, Haier J, et al. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998;13:164–8. Cross Ref link Pubmed link
67 Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue‐saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010;63:475–80. Cross Ref link Pubmed link
68 Van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 2012;26:898–902. Cross Ref link Pubmed link
69 Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping‐secondary intention technique. Br J Dermatol 1994;131:551–6. Cross Ref link Pubmed link
70 Mikkelsen PR, Dufour DN, Zarchi K, et al. Recurrence rate and patient satisfaction of CO2 laser evaporation of lesions in patients with hidradenitis suppurativa: a retrospective study. Dermatol Surg 2015;41:255–60. Cross Ref link Pubmed link
71 Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg 2012;38:517–36. Cross Ref link Pubmed link
72 Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium‐doped yttrium aluminium garnet laser. Dermatol Surg 2009;35:1188–98. Cross Ref link Pubmed link
73 Highton L, Chan WY, Khwaja N, et al. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 2011;128:459–65. Cross Ref link Pubmed link
74 Trombetta M, Werts ED, Parda D. The role of radiotherapy in the treatment of hidradenitis suppurativa: case report and review of the literature. Dermatol Online J 2010;16:16. Pubmed link

Log in to Rooks online